April 9 (Reuters) - Indian pharmaceutical stocks .NIPHARM fell 1.7% on Wednesday after U.S. President Donald Trump reiterated plans to announce a "major" tariff on all pharmaceutical imports.
U.S. accounts for a third of India's overall pharma exports.
Trump also threatened the duties on Friday, after his first set of reciprocal tariffs earlier last week exempted pharma products -- a change in stance that had prompted a wild swing in pharma stocks.
On the day, all twenty constituents of the pharma index were lower, with the index dragging down the benchmark Nifty 50 .NSEI by about 0.52% as of 9:20 a.m. IST.
Gland Pharma GLAD.NS, Lupin LUPN.NS and Zydus Lifesciences ZYDU.NS were the top losers by percentage, down between 3% and 5%.
Sun Pharma SUN.NS and Cipla CIPL.NS, the top constituents by weight, fell 1.69% and 1.87%, respectively.
India's pharma exports to the U.S. mostly comprise generics, or cheaper versions of popular drugs. These currently attract almost no U.S. levies, while India imposes about 10% tax on U.S. pharma imports, according to industry experts.
The pharma index has fallen 14.4% this year.
(Reporting by Kashish Tandon and Ananta Agarwal in Bengaluru; Editing by Savio D'Souza)
((Ananta.agarwal@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。